Genovac
Genovac is a contract research and manufacturing organization (CRO/CMO) focused on discovery, development, and production of antibodies. The company combines genetic immunization, multiple host species, single B cell screening, hybridoma workflows, and downstream production to generate and characterize antibodies against challenging targets, including multi-pass membrane proteins. Operations include discovery activities in Germany and production and characterization capabilities at a headquarters facility in Fargo, North Dakota.
Industries
Nr. of Employees
small (1-50)
Genovac
North Dakota State University Research & Technology Park, Fargo, ND, USA (headquarters and production/characterization site)
Patents
Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection
US-8518408-B2
View Details
Monoclonal anti-claudin 1 antibodies for the inhibition of hepatitis C virus infection
US-8518408-B2
View DetailsProducts
Catalog antibodies (panel of monoclonal and polyclonal antibodies)
Off-the-shelf panel of characterized antibodies against a range of human and other targets for use in applications such as flow cytometry, ELISA, immunofluorescence, western blot, and immunohistology.
Catalog antibodies (panel of monoclonal and polyclonal antibodies)
Off-the-shelf panel of characterized antibodies against a range of human and other targets for use in applications such as flow cytometry, ELISA, immunofluorescence, western blot, and immunohistology.
Services
Discovery workflows combining genetic immunization, multiple host species options, hybridoma workflows, and single B cell screening to generate antibodies against challenging targets.
Parallel small-scale high-throughput production, intermediate batch production, and scale-up mammalian production with downstream process development support.
Label-free binding kinetics and epitope binning workflows to support lead selection and epitope mapping using high-throughput SPR and BLI platforms.
Design and execution of customized functional assays (binding, blocking, neutralization, internalization, cytotoxicity) with multiple detection platforms.
Generation and selection of production cell lines using automated single-cell platforms to support recombinant antibody manufacture.
Integration of cloud-based analytics platforms to accelerate discovery workflows and aid early de-risking of antibody candidates.
Discovery workflows combining genetic immunization, multiple host species options, hybridoma workflows, and single B cell screening to generate antibodies against challenging targets.
Parallel small-scale high-throughput production, intermediate batch production, and scale-up mammalian production with downstream process development support.
Label-free binding kinetics and epitope binning workflows to support lead selection and epitope mapping using high-throughput SPR and BLI platforms.
Design and execution of customized functional assays (binding, blocking, neutralization, internalization, cytotoxicity) with multiple detection platforms.
Generation and selection of production cell lines using automated single-cell platforms to support recombinant antibody manufacture.
Integration of cloud-based analytics platforms to accelerate discovery workflows and aid early de-risking of antibody candidates.
Expertise Areas
- Antibody discovery and screening
- Genetic immunization
- Single B cell workflows and single-cell screening
- Hybridoma development
Key Technologies
- Genetic immunization
- Single-cell automated screening platforms
- Hybridoma technology
- Surface plasmon resonance (high-throughput SPR)
News & Updates
Webinar covering discovery of therapeutic and diagnostic antibody candidates and generative deep learning-based humanization approaches.
Webinar on using genetic immunization to improve diversity and affinity of anti-idiotypic antibodies.
Article discussing the impact of automated single-cell platforms on antibody discovery timelines and outcomes.
Coverage of collaborative efforts and platform use to address difficult antibody discovery problems.
Reported completion of over 3,600 antibody discovery projects.
Stated ~25 years of experience in antibody discovery.
Webinar covering discovery of therapeutic and diagnostic antibody candidates and generative deep learning-based humanization approaches.
Webinar on using genetic immunization to improve diversity and affinity of anti-idiotypic antibodies.
Article discussing the impact of automated single-cell platforms on antibody discovery timelines and outcomes.
Coverage of collaborative efforts and platform use to address difficult antibody discovery problems.
Reported completion of over 3,600 antibody discovery projects.
Stated ~25 years of experience in antibody discovery.